Actively Recruiting
Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer
Led by Rambam Health Care Campus · Updated on 2024-01-09
200
Participants Needed
1
Research Sites
257 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In women with cervical cancer -Squamous cell carcinoma, Adeno carcinoma, Adeno-squamous carcinoma or AIS we want to examine prospectively: 1. Examine if negative HR-HPV after conization to the HR-HPV the women had before conization has a high prognostic value for no residual tumor in the final pathology. 2. To examine if conization in women with cervical tumor up to Stage I B 2 (FIGO 2018) is corelated with better prognosis.
CONDITIONS
Official Title
Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 85 years
- Diagnosed with cervical cancer stage IB2 (tumor up to 4 cm, FIGO 2018)
- Diagnosed with adenocarcinoma in situ (AIS)
- Available HPV typing data before and after conization
You will not qualify if you...
- Pregnant women under 18 years old
- Women who refuse to continue participation in the study
- Women missing data on HPV types, final pathology, or complications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rambam Health Care Center
Haifa, Israel, 31906
Actively Recruiting
Research Team
Y
Yoav Siegler, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here